Related Experiment Video

Updated: Jul 19, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Beta-cell preservation with thiazolidinediones

Ian W Campbell1, Segundo Mariz

  • 1Victoria Hospital, Kirkcaldy, Fife, Scotland.

Diabetes Research and Clinical Practice
|October 21, 2006
PubMed

Insights

Thiazolidinediones (TZDs) improve beta-cell function and preserve pancreatic beta-cell mass, potentially delaying or preventing type 2 diabetes onset in high-risk individuals. These findings highlight TZDs

Area of Science:

  • Endocrinology and Metabolism
  • Diabetes Pathophysiology

Background:

  • Type 2 diabetes is characterized by progressive beta-cell dysfunction and failure to overcome insulin resistance.
  • Preventing diabetes progression requires strategies to stabilize the decline of pancreatic beta-cell function.

Purpose of the Study:

  • To review evidence on the effects of thiazolidinediones (TZDs) on beta-cell function.
  • To evaluate the impact of TZDs on preventing or delaying type 2 diabetes onset.

Main Methods:

  • Review of in vitro studies investigating TZD mechanisms.
  • Analysis of clinical intervention trials assessing TZD efficacy in high-risk individuals.

Main Results:

  • TZDs enhance insulin secretory capacity and preserve beta-cell mass and islet structure.
  • TZDs protect beta-cells from oxidative stress, improving function measures like insulinogenic index and HOMA-%B.
  • Intervention studies indicate TZDs can delay, stabilize, or prevent diabetes onset, linked to improved beta-cell function.

Conclusions:

  • TZDs demonstrate significant benefits for beta-cell health and function.
  • Evidence supports TZDs' potential role in delaying or preventing type 2 diabetes in at-risk populations.
  • Understanding TZD effects on beta-cells is crucial for glucose-lowering therapy development.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...